{"filing":{"accession_number":"0001104659-26-105905","cik":"0001001233","ticker":"SGMO","company_name":"SANGAMO THERAPEUTICS, INC","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-02","primary_document":"tm2624942d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1001233/000110465926105905/tm2624942d1_8k.htm"},"events":[{"id":31960,"run_id":29356,"accession_number":"0001104659-26-105905","anchor_item_number":"1.03","event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.99,"summary":"Sangamo Therapeutics, Inc. filed a voluntary Chapter 11 bankruptcy petition on June 23, 2026, in the United States Bankruptcy Court for the District of Delaware (Case No. 26-10989). The company is operating as a debtor-in-possession, with its common stock delisted from Nasdaq and trading on the OTCID Basic Market.","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":35007,"accession_number":"0001104659-26-105905","item_number":"1.03","item_title":null,"event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.99,"reasoning":"Sangamo Therapeutics, Inc. filed a voluntary Chapter 11 bankruptcy petition on June 23, 2026, in the United States Bankruptcy Court for the District of Delaware (Case No. 26-10989). The 8-K Item 1.03 explicitly incorporates this bankruptcy filing, and the attached monthly operating report (MOR) confirms the debtor-in-possession status and ongoing bankruptcy proceedings. This is a terminal event materially threatening the registrant's continued existence.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T20:09:25.227333+00:00","company_name":"","ticker":null,"filing_date":""},{"id":35009,"accession_number":"0001104659-26-105905","item_number":"7.01","item_title":null,"event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"Sangamo Therapeutics filed a voluntary Chapter 11 bankruptcy petition on June 23, 2026, and this 8-K Item 7.01 discloses the company's monthly operating report (MOR) for the period ended July 31, 2026, filed with the bankruptcy court. The filing explicitly references \"Case No. 26-10989\" and the company's status as a debtor-in-possession. The cautionary language warns that \"trading in the Company's common stock during the pendency of the Chapter 11 Case is highly speculative\" and notes the stock has been delisted from Nasdaq and is trading on the OTCID Basic Market. This is a terminal event materially threatening the registrant's continued existence.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T20:09:25.227333+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":31961,"run_id":29356,"accession_number":"0001104659-26-105905","anchor_item_number":"2.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Sangamo Therapeutics completed a material asset sale to Eli Lilly and Company on September 4, 2026, pursuant to a court-approved Asset Purchase Agreement dated June 22, 2026. The transaction involved the sale of substantially all of the Company's core technology platforms (AAV capsid engineering, zinc finger protein technology, Modular Integrase genome editing, prion disease program, and related IP) for $50 million in cash plus assumption of specified liabilities.","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":35008,"accession_number":"0001104659-26-105905","item_number":"2.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the completion of a material asset sale by Sangamo Therapeutics to Eli Lilly and Company on September 4, 2026, pursuant to a court-approved Asset Purchase Agreement dated June 22, 2026. The transaction involved the sale of substantially all of the Company's core technology platforms (AAV capsid engineering, zinc finger protein technology, Modular Integrase genome editing, prion disease program, and related IP) for $50 million in cash plus assumption of specified liabilities. This constitutes a material disposition of assets under Item 2.01, occurring within the context of the Company's Chapter 11 bankruptcy proceeding that commenced June 23, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T20:09:25.227333+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35007,"accession_number":"0001104659-26-105905","item_number":"1.03","item_title":null,"event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.99,"reasoning":"Sangamo Therapeutics, Inc. filed a voluntary Chapter 11 bankruptcy petition on June 23, 2026, in the United States Bankruptcy Court for the District of Delaware (Case No. 26-10989). The 8-K Item 1.03 explicitly incorporates this bankruptcy filing, and the attached monthly operating report (MOR) confirms the debtor-in-possession status and ongoing bankruptcy proceedings. This is a terminal event materially threatening the registrant's continued existence.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T20:09:25.227333+00:00","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-09-08"},{"id":35008,"accession_number":"0001104659-26-105905","item_number":"2.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the completion of a material asset sale by Sangamo Therapeutics to Eli Lilly and Company on September 4, 2026, pursuant to a court-approved Asset Purchase Agreement dated June 22, 2026. The transaction involved the sale of substantially all of the Company's core technology platforms (AAV capsid engineering, zinc finger protein technology, Modular Integrase genome editing, prion disease program, and related IP) for $50 million in cash plus assumption of specified liabilities. This constitutes a material disposition of assets under Item 2.01, occurring within the context of the Company's Chapter 11 bankruptcy proceeding that commenced June 23, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T20:09:25.227333+00:00","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-09-08"},{"id":35009,"accession_number":"0001104659-26-105905","item_number":"7.01","item_title":null,"event_type":"bankruptcy_filing","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"Sangamo Therapeutics filed a voluntary Chapter 11 bankruptcy petition on June 23, 2026, and this 8-K Item 7.01 discloses the company's monthly operating report (MOR) for the period ended July 31, 2026, filed with the bankruptcy court. The filing explicitly references \"Case No. 26-10989\" and the company's status as a debtor-in-possession. The cautionary language warns that \"trading in the Company's common stock during the pendency of the Chapter 11 Case is highly speculative\" and notes the stock has been delisted from Nasdaq and is trading on the OTCID Basic Market. This is a terminal event materially threatening the registrant's continued existence.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T20:09:25.227333+00:00","company_name":"SANGAMO THERAPEUTICS, INC","ticker":"SGMO","filing_date":"2026-09-08"}]}